Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 25
Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 26
Apr 24, 2024, 09:58
KEYNOTE-A18 summarised by Sergio Cifuentes
Sergio Cifuentes, Cancer Research Project Manager at
”KEYNOTE-A18.
- Pembrolizumab + CRT in LACC
- mPFS NR in pembrolizumab group
24m PFS: 68% vs 57%
- Pembrolizumab + CRT led to a 30% reduction in DR
- OS at 24m: 87% vs 81%
Grade 3 or higher AE: 75% vs 69%.”
Read further.
Source: Sergio Cifuentes/X